Related Experiment Videos
Tissue specific susceptibility of alpha-adrenoceptor mediated vasoconstriction to nifedipine
Abstract:
The influence of the calcium antagonist nifedipine on alpha 1- and alpha 2-adrenoceptor-mediated vasoconstrictor effects was investigated in vitro. Changes in tension were monitored isometrically on helical strips of canine circumflex coronary and saphenous arteries suspended in 10 ml organ baths and of saphenous arteries suspended in 10 ml organ baths and of saphenous veins superfused with Krebs-Henseleit solution. Distinction between alpha 1- and alpha 2-adrenoceptors was made by using selective alpha-adrenoceptor blocking drugs such as rauwolscine, yohimbine, corynanthine and prazosin, and the agonists noradrenaline, phenylephrine and guanfacine. In venous and both arterial vascular smooth muscles, the contractile process could be triggered by stimulation of both alpha 1- and alpha 2-like adrenoceptors. Nifedipine inhibited the venoconstrictor response to the alpha 2-agonist guanfacine, leaving that to the alpha 1-agonist phenylephrine unchanged. In saphenous arteries, nifedipine in addition to guanfacine also antagonized constrictor responses to phenylephrine, though to a significantly weaker extent. In circumflex coronary arteries, nifedipine was equally potent in antagonizing responses to both alpha 1- and alpha 2-adrenoceptor stimulation. It is suggested that the susceptibility of alpha-adrenoceptor-mediated vasoconstrictor effects to blockade by calcium antagonists depends not only on the subtype of alpha-adrenoceptor but, in addition, on the type and origin of vascular smooth muscle and may be a reflection of tissue variations in intracellular calcium stores.
Insights
Calcium channel blocker nifedipine differentially affects alpha-1 and alpha-2 adrenoceptor vasoconstriction. Its potency varies by blood vessel type, suggesting tissue-specific calcium handling influences drug response.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Vascular Biology
Background:
- Alpha-1 and alpha-2 adrenoceptors mediate vasoconstriction.
- Calcium plays a critical role in vascular smooth muscle contraction.
- Calcium channel blockers like nifedipine are used to treat hypertension.
Purpose of the Study:
- To investigate the in vitro effects of nifedipine on alpha-1 and alpha-2 adrenoceptor-mediated vasoconstriction.
- To determine if nifedipine's inhibitory effects differ between alpha-1 and alpha-2 adrenoceptor stimulation.
- To explore the influence of vascular bed origin on nifedipine's action.
Main Methods:
- Isometric tension monitoring on isolated canine coronary and saphenous arteries and saphenous veins.
- Use of selective alpha-adrenoceptor agonists (phenylephrine, guanfacine) and antagonists.
- Application of nifedipine to assess its blockade of adrenoceptor-mediated contractions.
Main Results:
- Nifedipine inhibited alpha-2-mediated venoconstriction by guanfacine but not alpha-1-mediated contraction by phenylephrine.
- In saphenous arteries, nifedipine weakly antagonized phenylephrine-induced contraction.
- Nifedipine equally inhibited both alpha-1 and alpha-2 mediated vasoconstriction in circumflex coronary arteries.
Conclusions:
- Nifedipine's blockade of alpha-adrenoceptor-mediated vasoconstriction is dependent on the adrenoceptor subtype.
- The vascular origin and type of smooth muscle influence nifedipine's efficacy.
- Tissue variations in intracellular calcium stores may explain differential responses to nifedipine's blockade.